Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB) Patients were ...

NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience ...

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase ...

Clinical research and health tech companies Medidata and Cogstate are joining forces to speed up trials and improve outcomes measurement across diseases of the central nervous system, the partners ...

CNS metastases in EGFR-mutant NSCLC are prevalent and worsen prognosis, especially with acquired progression during treatment. Amivantamab plus lazertinib shows promising CNS activity, but current ...

Central nervous system (CNS) clinical trials are among the most scientifically complex and operationally demanding in life sciences. The need to evaluate nuanced cognitive, behavioral, and emotional ...